* has a known history of sars-cov-2 infection (that is, reported ae of covid-19 or asymptomatic sars-cov-2 infection during study mrna-1273-p204 at the time of rollover into mrna-1273-p306 or during part 1 at the time of rollover into part 3) in the 90 days prior to dosing in this study. * is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°celsius (c)/≥ 100.4°fahrenheit (f). participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. * for parts 1 and 4, participant has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus \[mers-cov\]) vaccine. for part 2, participant who received any approved/investigational cov vaccine are ineligible to participate except for those who received mrna-1273 (prototype) vaccine. * has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. * has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol \[peg\] or immediate allergic reaction of any severity to polysorbate). * has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. * has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: * congenital or acquired immunodeficiency, other than well-controlled hiv infection. * chronic hepatitis or suspected active hepatitis * a bleeding disorder that is considered a contraindication to im injection or phlebotomy * dermatologic conditions that could affect local solicited ar assessments * any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) * has received the following: * any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). * systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs \>10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. * intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment. note: other inclusion and exclusion criteria may apply.

* has a known history of sars-cov-2 infection (that is, reported ae of covid-19 or asymptomatic sars-cov-2 infection during study mrna-1273-p204 at the time of rollover into mrna-1273-p306 or during part 1 at the time of rollover into part 3) in the 90 days prior to dosing in this study. * is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°celsius (c)/≥ 100.4°fahrenheit (f). participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. * for parts 1 and 4, participant has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus \[mers-cov\]) vaccine. for part 2, participant who received any approved/investigational cov vaccine are ineligible to participate except for those who received mrna-1273 (prototype) vaccine. * has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. * has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol \[peg\] or immediate allergic reaction of any severity to polysorbate). * has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. * has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: * congenital or acquired immunodeficiency, other than well-controlled hiv infection. * chronic hepatitis or suspected active hepatitis * a bleeding disorder that is considered a contraindication to im injection or phlebotomy * dermatologic conditions that could affect local solicited ar assessments * any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) * has received the following: * any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). * systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs \>10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. * intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment. note: other inclusion and exclusion criteria may apply.

has a known history of sars-cov-2 infection (that is, reported ae of covid-19 or asymptomatic sars-cov-2 infection during study mrna-1273-p204 at the time of rollover into mrna-1273-p306 or during part 1 at the time of rollover into part 3) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°celsius (c)/≥ 100.4°fahrenheit (f). participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. for parts 1 and 4, participant has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, participant who received any approved/investigational cov vaccine are ineligible to participate except for those who received mrna-1273 (prototype) vaccine. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment. note: other inclusion and exclusion criteria may apply.

has a known history of sars-cov-2 infection (that is, reported ae of covid-19 or asymptomatic sars-cov-2 infection during study mrna-1273-p204 at the time of rollover into mrna-1273-p306 or during part 1 at the time of rollover into part 3) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°celsius (c)/≥ 100.4°fahrenheit (f). participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. for parts 1 and 4, participant has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, participant who received any approved/investigational cov vaccine are ineligible to participate except for those who received mrna-1273 (prototype) vaccine. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment. note: other inclusion and exclusion criteria may apply.

has a known history of sars-cov-2 infection (that is, reported ae of coronavirus disease 2019 [covid-19] or asymptomatic sars-cov-2 infection during study mrna-1273-p204) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°c/≥ 100.4°f. participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, this applies to vaccines other than the mrna-1273 (prototype) vaccine. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment.

has a known history of sars-cov-2 infection (that is, reported ae of coronavirus disease 2019 [covid-19] or asymptomatic sars-cov-2 infection during study mrna-1273-p204) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°c/≥ 100.4°f. participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, this applies to vaccines other than the mrna-1273 (prototype) vaccine. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (including receipt of sars-cov-2 monoclonal antibodies for prophylaxis or treatment) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids, and palivizumab are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment.

has a known history of sars-cov-2 infection (that is, reported ae of coronavirus disease 2019 [covid-19] or asymptomatic sars-cov-2 infection during study mrna-1273-p204) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°c/≥ 100.4°f. participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, this applies to vaccines other than mrna-1273. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (that is, receipt of sars-cov-2 monoclonal antibodies) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment.

has a known history of sars-cov-2 infection (that is, reported ae of coronavirus disease 2019 [covid-19] or asymptomatic sars-cov-2 infection during study mrna-1273-p204) in the 90 days prior to dosing in this study. is acutely ill or febrile 24 hours prior to or at the screening visit. fever is defined as a body temperature ≥ 38.0°c/≥ 100.4°f. participants who meet this criterion may have visits rescheduled within the relevant study visit windows. afebrile participants with minor illnesses can be enrolled at the discretion of the investigator. has previously been administered an investigational or approved cov (that is, sars-cov-2, sars-cov, middle east respiratory syndrome coronavirus [mers-cov]) vaccine. for part 2, this applies to vaccines other than mrna-1273. has undergone treatment with investigational or approved agents for prophylaxis against covid-19 (that is, receipt of sars-cov-2 monoclonal antibodies) within 90 days prior to enrollment. has a known hypersensitivity to a component of the vaccine or its excipients. hypersensitivity includes, but is not limited to, anaphylaxis or immediate allergic reaction of any severity to a previous dose of an mrna covid-19 vaccine or any of its components (including polyethylene glycol [peg] or immediate allergic reaction of any severity to polysorbate). has a medical or psychiatric condition that, according to the investigator's judgment, may pose additional risk as a result of participation, interfere with safety assessments, or interfere with interpretation of results. has a history of diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety, specifically the following: congenital or acquired immunodeficiency, other than well-controlled hiv infection. chronic hepatitis or suspected active hepatitis a bleeding disorder that is considered a contraindication to im injection or phlebotomy dermatologic conditions that could affect local solicited ar assessments any prior diagnosis of malignancy (excluding nonmelanoma skin cancer) has received the following: any routine vaccination with inactivated or live vaccine(s) within 14 days prior to study vaccination or plans to receive such a vaccine through 14 days following study vaccination. note: this excludes influenza vaccine that may be given anytime, but ideally at least 7 days before study dose. if a participant receives an influenza vaccine, this should be captured within the concomitant medication electronic case report form (ecrf). systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to the day of enrollment (for corticosteroids, ≥1 milligrams (mg)/kg/day or ≥ 10 mg/day prednisone equivalent, if participant weighs >10 kg). participants may have visits rescheduled for enrollment if they no longer meet this criterion within the screening visit window. inhaled, nasal, and topical steroids are allowed. intravenous (iv) or subcutaneous (sc) blood products (red cells, platelets, immunoglobulins) within 3 months prior to enrollment.